Sepsis - the challenges of science, politics and society
Start:
Thu, 10 Mar 2016, 10:30
End:
Fri, 11 Mar 2016, 05:10
Venue:
Exhibit
Symposia
Workshops
Organiser
Sponsor
- Increase vaccination rates and adherence to hygienic standards
- Improve preparedness in case of further pandemics
- Increase awareness for sepsis among lay people and health
care providers
- Foster quality improvement projects in the hospital and
outpatient setting
- Implement antibiotic stewardship programs and stop the
misuse of antimicrobials
- Overcome the gap between resistance, novel and effective
antimicrobials
- Encourage the development of cost-effective diagnostics and
sepsis-specific therapeutics
- Develop and provide adequate treatment concepts for sepsis
sequelae
Participation at the symposium is free of charge, but registration is required.
Please fill the form for ONLINE REGISTRATION
Program Thursday, 10 March 2016 | |
Opening session | |
Chairs: | |
E. Rietschel, Berlin / P. Suter, Geneva | |
Start: 10:30 | |
Welcome and introduction | |
W. Tiefensee, TMWWDG | G. Berg, Leopoldina |
W. Rosenthal, FSU | K. Benndorf, UKJ |
10:50 Keynote Lecture: | |
Role of poverty and environment for public health | |
A. Steiner, Executive Director of United Nations Environment Programme (UNEP) and Under-Secretary-General of the United Nations | |
11:20 | |
The German strategy for infection and sepsis control | |
L. H. Wieler, RKI | |
11:40 | |
The WHO approach to sepsis control | |
N. Shindo, WHO | |
12:00 | |
Lessons to be learned from the Ebola epidemic | |
T. Stöbe, MSF | |
12:20 | |
The burden of sepsis in children | |
N. Kissoon, Canada | |
12:40 | |
The burden of sepsis - a call to action | |
K. Reinhart, Jena | |
13:00 Lunch Break | |
The challenges of science | |
Chairs: | |
M. Quintel, Göttingen / T. Hein, Dallas | |
14:00 | |
Challenges in the development of novel diagnostics and therapeutics in sepsis | |
N. Riedemann, Jena | |
14:20 | |
Challenges to preserve and develop effective antimicrobials | |
M. Pletz, Jena | |
14:40 | |
Role and challenges of clinical sepsis research | |
S. Finfer, Australia | |
15:00 | |
Lessons learned from cancer | |
M. Löffler, Leipzig | |
15:20 | |
Lessons learned from cardiology | |
C. Schulze, Jena | |
15:40 Coffee Break | |
Novel approaches to sepsis control and health promotion | |
Chairs: | |
C. Spies, Berlin / R. Rossaint, Aachen | |
16:00 | |
The Surviving Sepsis Campaign approach to guideline implementation | |
H. Gerlach, Berlin | |
16:20 | |
The National Irish initiative to sepsis control | |
V. Hamilton, Ireland | |
16:40 | |
The Scottish National Health Service approach to quality improvement | |
K. Rooney, Scotland | |
Novel approaches to sepsis control and health promotion II | |
Chairs: | |
K. Werdan, Halle / M. Weigand, Heidelberg | |
17:00 | |
The NRC for Surveillance and Nosocomial infection’s approach | |
P. Gastmeier, Berlin | |
17:20 | |
The Initiative for Quality in Medicine’s approach | |
A. Meier-Hellmann, Erfurt | |
17:40 | |
The Center for Sepsis Control and Care’s approach | |
H. Rüddel, Jena | |
18:00 | |
The perspective of a sepsis victim | |
A. Trumann, Heeslingen | |
Öffentlicher Abendvortrag | |
Moderation: | |
M. Bucher, Halle | |
19:00 | |
Sepsis vermeiden und früh erkennen | |
F. M. Brunkhorst, Jena | |
Program Friday, 11 March 2016 | |
Novel approaches to sepsis control and health promotion | |
Chairs: | |
B. Böttiger, Cologne / B. Löffler, Jena | |
08:30 | |
The US approach to quality improvement for sepsis management | |
M. Levy, USA | |
08:50 | |
The UK Sepsis Trust approach to awareness & quality improvement | |
R. Daniels, UK | |
09:10 | |
Prepardness and the role of ICUs in the fight against pandemics | |
J. Marshall, Canada | |
09:30 | |
The Turkish approach to improve sepsis awareness and sepsis management. | |
N. Unal, Turkey | |
09:50 | |
The role of media during health crises | |
J. Müller-Jung, FAZ | |
10:10 | |
New approaches to vaccination and health promotion | |
C. Betsch, Erfurt | |
10:30 Coffee break | |
Roadmap for development of innovative vaccines, diagnostics and therapeutics I | |
Chairs: | |
T. Koch, Dresden / L. Gattinoni, Milan | |
Role of private public partnership for development of innovative vaccines, diagnostics and therapeutics Lessons learned and expectations of: | |
Chairs: | |
M. Hecker, Greifswald / H. van Aken, Münster | |
15:30 | |
A researcher and later entrepreneur | |
E. Ermantraut, Blink GmbH Jena | |
15:50 | |
An international diagnostics corporate | |
V. Liebenberg, Thermo Fisher Scientific Hennigsdorf/Berlin | |
16:10 | |
A global medical products manufacturer | |
M. Lugan, B. Braun Melsungen AG | |
16:30 | |
A biotech company | |
J. Struck, AdrenoMed AG Hennigsdorf/Berlin | |
16:50 | |
A university spin-off | |
N. Riedemann, inflaRx Jena | |
17:10 Closing remarks | |
M. Bauer, Jena |
More events
Sat, 5 Oct 2024 - Wed, 9 Oct 2024
Barcelona, 08019
Spain
Mon, 7 Oct 2024 - Fri, 11 Oct 2024
Tue, 8 Oct 2024 - Thu, 10 Oct 2024
Wed, 9 Oct 2024 - Sat, 12 Oct 2024
Fri, 11 Oct 2024 - Sat, 12 Oct 2024
Sun, 13 Oct 2024 - Wed, 16 Oct 2024
Tue, 15 Oct 2024 - Wed, 16 Oct 2024
Fri, 18 Oct 2024 - Tue, 22 Oct 2024
Fri, 18 Oct 2024 - Sat, 19 Oct 2024
Fri, 25 Oct 2024 - Sat, 26 Oct 2024